Li Bang International Stock (NASDAQ: LBGJ)

Li Bang International (NASDAQ:LBGJ) Stock, Quote.Headers.trade-ideas

Li Bang International

Li Bang International Corp Inc is a holding company. The firm through its subsidiaries engages in designing, developing, producing, and selling stainless steel commercial kitchen equipment in China under its own Libang brand. In addition, its subsidiaries provide customers with comprehensive services, from commercial kitchen design in the early stage to equipment installation and after-sales maintenance.

Li Bang International Corporation Inc. - Ordinary Shares

Li Bang International Corp Inc

HC Wainwright &amp; Co. analyst Robert Burns reiterates Cogent Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COGT#NASDAQ">COGT</a>) from Buy to Buy.

News

Reiteration

Analyst Ratings

COGT

HC Wainwright & Co. Reiterates Buy on Cogent Biosciencesto Buy

Leerink Partners analyst Thomas Smith downgrades Q32 Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTTB#NASDAQ">QTTB</a>) from Outperform to Market Perform and lowers the price target from $68 to $9.

Downgrades

Price Target

QTTB

Leerink Partners Downgrades Q32 Bio to Market Perform, Lowers Price Target to $9

Bernstein analysts have spotlighted MicroStrategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) as a <a href="https://www.benzinga.com/insights/options/24/12/42273542/smart-money-is-betting-big-in-mstr-options">potential inclusion in the Nasdaq 100</a>, a move that could significantly boost the company's visibility and attract fresh inflows from major ETFs like (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>).
This development, coupled with MicroStrategy's aggressive Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) acquisition strategy, led Bernstein to set a $600 target price for the company, representing a 59% upside from its current valuation.
Bloomberg Intelligence's report suggests that Nasdaq 100 inclusion could bring substantial one-time and ongoing inflows to MicroStrategy, estimated at $2.1 billion initially. 
The company has rapidly scaled its Bitcoin holdings, purchasing approximately <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42391481/microstrategy-acquires-21b-worth-of-bitcoin-total-holdings-now-exceed-423000-btc">$16 billion worth in just 40 days</a>—around 40% of its total Bitcoin position.
Also Read: <a href="https://www.benzinga.com/markets/24/12/42424139/microsoft-shareholders-to-vote-on-bitcoin-investment-proposal">Microsoft Shareholders To Vote On Bitcoin Investment Proposal</a>
Analysts note that while MicroStrategy trades at a 147% premium to its Bitcoin net asset value (NAV), the valuation premium is expected to normalize as the company continues accumulating Bitcoin. 
Bernstein analysts emphasized, &#8220;MicroStrategy&#8217;s ability to issue equity and convertible debt at this premium makes its current strategy sustainable through at least 2025.&#8221;
Looking beyond Nasdaq 100 inclusion, Bernstein pointed to the possibility of MicroStrategy <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42253555/microstrategys-imminent-inclusion-in-nasdaq-100-could-reportedly-spark-up-to-2b-in-fund-inflows">joining the S&amp;P 500</a> in 2025.
This prospect hinges on the company's ability to recognize unrealized gains on its Bitcoin position—currently valued at $41 billion—under new Financial Accounting Standards Board (FASB) rules set to take effect in 2025.
Despite a substantial run-up in MicroStrategy's stock price post-election, analysts view the current levels as a reasonable entry point, citing the <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42422705/donald-trump-would-welcome-150000-bitcoin-early-in-presidency-its-another-stock-market-for-him">supportive regulatory environment</a> under the Donald Trump administration.
"The company's flywheel effect, driven by Bitcoin purchases and potential index inclusions, is likely to accelerate from here," Bernstein stated.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42423570/ripple-secures-nydfs-approval-for-rlusd-stablecoin-xrp-price-up-9">Ripple Secures NYDFS Approval for RLUSD Stablecoin: XRP Price Up 9%</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

MSTR

MicroStrategy: Nasdaq 100 Inclusion On The Horizon Could Spell 59% Upside, Says Bernstein

Earnings

General

Macy's Q3 2024 Adj $0.04 Beats $0.03 Estimate, Sales $4.74B Beat $4.72B Estimate

As of Dec. 11, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the <a href="https://www.benzinga.com/topic/rsi">RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Adaptive Biotechnologies Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>)</h3>
<ul>
<li>On Dec. 7, Adaptive Biotechnologies presented new data at ASH 2024 showcasing clonoSEQ MRD testing advances and its role in guiding blood cancer treatment decisions. The company's shares gained around 6% over the past month and has a <a href="https://www.benzinga.com/quote/ADPT">52-week high of $7.07</a>.</li>
<li>RSI Value: 75.83&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>ADPT Price Action: Shares of Adaptive Biotechnologies gained 4.2% to close at $6.71 on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">NewAmsterdam Pharma Company NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>)</h3>
<ul>
<li>On Dec. 10, NewAmsterdam Pharma revealed topline data from its Phase 3 BROADWAY clinical trial evaluating obicetrapib in adult patients with atherosclerotic cardiovascular disease (ASCVD) and/or heterozygous familial hypercholesterolemia (HeFH), whose LDL-C is not adequately controlled, despite being on maximally tolerated lipid-lowering therapy. The company's stock gained around 30% over the past five days and <a href="https://www.benzinga.com/quote/NAMS">has a 52-week high</a> of $26.36.</li>
<li>RSI Value: 81.17</li>
<li>NAMS Price Action: Shares of NewAmsterdam Pharma jumped 41.4% to close at $26.19 on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Paragon 28 Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNA#NYSE">FNA</a>)</h3>
<ul>
<li>On Nov. 12, Paragon 28 reported quarterly losses of 15 cents per share which met the analyst consensus estimate. The company reported quarterly sales of $62.30 million which beat the analyst consensus estimate of $60.58 million. The company's stock gained around 38% over the past month and has a <a href="https://www.benzinga.com/quote/FNA">52-week high</a> of $14.79.</li>
<li>RSI Value: 77.07</li>
<li>FNA Price Action: Shares of Paragon 28 gained 5% to close at $10.50 on Tuesday. </li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/12/42429201/dow-falls-for-4th-straight-session-alphabet-surges-on-google-quantum-chip-announcement-fear-greed-index-remains-in-neutral-zone">Dow Falls For 4th Straight Session, Alphabet Surges On Google Quantum Chip Announcement: Fear &amp; Greed Index Remains In &#8216;Neutral&#8217; Zone</a></li>
</ul>

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

ADPT

NAMS

Top 3 Health Care Stocks That May Collapse This Quarter

PDCO

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

Leerink Partners analyst Faisal Khurshid initiates coverage on ANI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIP#NASDAQ">ANIP</a>) with a Outperform rating and announces Price Target of $80.

Initiation

ANIP

Leerink Partners Initiates Coverage On ANI Pharmaceuticals with Outperform Rating, Announces Price Target of $80

Needham analyst Quinn Bolton reiterates Mobileye Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) with a Buy and maintains $20 price target.

MBLY

Needham Reiterates Buy on Mobileye Global, Maintains $20 Price Target

JP Morgan analyst Pinjalim Bora downgrades C3.ai (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) from Neutral to Underweight and announces $28 price target.

JP Morgan Downgrades C3.ai to Underweight, Announces $28 Price Target

Nova Minerals Announces Gold Rock Chip Assay Results From Its 2024 Exploration Season Confirming An Extensive 800M Long By 400M Wide Gold And Antimony Rich Zone At Its Stibium Prospect, Within Its Over 500KM Flagship Estelle Gold And Critical Minerals Project In The Tintina Gold Belt In Alaska

JP Morgan analyst Pinjalim Bora downgrades PagerDuty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PD#NYSE">PD</a>) from Neutral to Underweight and announces $21 price target.

JP Morgan Downgrades PagerDuty to Underweight, Announces $21 Price Target

SCKT

Socket Mobile Announced A New Update To Its React Native CaptureSDK To Supports The React Native Version 0.75.4 And Enables Developers To Customize The SocketCam Viewfinder Within Their Applications

LNZA

LanzaTech And ArcelorMittal Announced That Ethanol From ArcelorMittal's Commercial Flagship Steelanol Facility In Belgium Has Achieved A Production Milestone Whereby Ethanol Volumes Have Ramped To A Significant Enough Level To Support Large-scale Shipping By Barge

JP Morgan analyst Pinjalim Bora downgrades Sprinklr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) from Overweight to Neutral and announces $11 price target.

JP Morgan Downgrades Sprinklr to Neutral, Announces $11 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Lisata Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSTA#NASDAQ">LSTA</a>) with a Buy and maintains $15 price target.

LSTA

HC Wainwright & Co. Reiterates Buy on Lisata Therapeutics, Maintains $15 Price Target

CYBR

CyberArk Announced The Launch Of FuzzyAI To Help Organizations Identify And Address AI Model Vulnerabilities, Like Guardrail Bypassing And Harmful Output Generation, In Cloud-hosted And In-house AI Models

Morgan Stanley analyst Ravi Shanker reinstates JetBlue Airways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) with a Equal-Weight and announces $8 price target.

JBLU

Morgan Stanley Reinstates Equal-Weight on JetBlue Airways, Announces $8 Price Target

Morgan Stanley analyst Ravi Shanker reinstates Southwest Airlines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) with a Overweight and announces $42 price target.

Morgan Stanley Reinstates Overweight on Southwest Airlines, Announces $42 Price Target

Goldman Sachs analyst Mark Delaney maintains Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) with a Neutral and raises the price target from $250 to $345.

TSLA

Goldman Sachs Maintains Neutral on Tesla, Raises Price Target to $345

Lucid Motors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) said on Tuesday that the company has got the official range estimate for its <a href="https://www.benzinga.com/topic/lucid-gravity">Gravity SUV</a> and it can drive longer on a single charge than its rival Tesla Model X.
What Happened: &#8220;It's official: The Lucid Gravity Grand Touring has an EPA-estimated range of up to 450 miles,&#8221; the company announced in a post on social media platform X. The EPA estimated range exceeds Lucid&#8217;s own projection of 440 miles. Gravity&#8217;s rival- the Tesla Model X- has a maximum range of only 329 miles. 
However, the Lucid SUV&#8217;s maximum range is below the maximum range of 512 miles offered on the Grand Touring variant of the company&#8217;s flagship vehicle- the Air sedan. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Range without compromise.​ ​ It's official: The Lucid Gravity Grand Touring has an EPA-estimated range of up to 450 miles. ​ ​ Configure yours today, and take the scenic route, every time: <a href="https://t.co/Gbwd8xeHaw">https://t.co/Gbwd8xeHaw</a> ​<a href="https://twitter.com/hashtag/LucidMotors?src=hash&amp;ref_src=twsrc%5Etfw">#LucidMotors</a> <a href="https://twitter.com/hashtag/Technology?src=hash&amp;ref_src=twsrc%5Etfw">#Technology</a> <a href="https://twitter.com/hashtag/EV?src=hash&amp;ref_src=twsrc%5Etfw">#EV</a> <a href="https://twitter.com/hashtag/ElectricVehicles?src=hash&amp;ref_src=twsrc%5Etfw">#ElectricVehicles</a> <a href="https://t.co/lwUXovbQ96">pic.twitter.com/lwUXovbQ96</a>
&mdash; Lucid Motors (@LucidMotors) <a href="https://twitter.com/LucidMotors/status/1866539711478497693?ref_src=twsrc%5Etfw">December 10, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Lucid started production of the Gravity SUV at the company&#8217;s factory in Arizona last week. 
Lucid&nbsp;<a href="https://www.benzinga.com/24/11/41838253/lucid-rises-nearly-5-in-pre-market-after-strong-q3-results-opening-orders-for-gravity-suv" target="_blank" rel="noreferrer noopener">started taking orders</a>&nbsp;for Gravity last month. Orders are now being taken for the Grand Touring trim of the SUV starting from $94,900. Production of the lower-priced Touring trim of the vehicle, starting at $79,900, will start only in late 2025, the company previously said.
Why It Matters: Lucid, which entered the EV market with its premium Air sedan, is looking to expand its total addressable market with Gravity. Rawlinson previously said that with Gravity, the company has now entered a "market that's about 6 times larger than our addressable market last year with Air."
The Gravity is expected to rival Model X SUV which starts at $79,990 for the base version and at $94,990 for the more premium Plaid version.
During Lucid's&nbsp;<a href="https://www.benzinga.com/news/24/05/38663810/lucid-ceo-throws-down-the-gauntlet-with-48k-ev-plan-to-take-on-teslas-dominance-wait-until-our-midsi" target="_blank" rel="noreferrer noopener">first-quarter earnings call in May</a>, the CEO said that Gravity has a &#8220;significant opportunity&#8221; that the Model X did not capture. While the Model X is a bit car-like, the Gravity is a proper three-row SUV and is on track to become the &#8220;world&#8217;s best SUV,&#8221; he said.
Lucid is also looking forward to starting production of a high-volume midsized platform priced at around $48,000 in late 2026 as a&nbsp;<a href="https://www.benzinga.com/news/24/06/39135581/youtuber-mkbhd-praises-lucid-air-sapphire-if-it-couldnt-be-a-tesla-it-would-have-to-be-this" target="_blank" rel="noreferrer noopener">direct competitor&nbsp;</a>to Tesla's mass-market offerings Model 3 and Model Y.
The company, however, is yet to make a profit. For the third quarter, the EV company reported an adjusted quarterly loss of 28 cents per share.
Price Action:&nbsp;Lucid shares closed down 7.45% on Tuesday at $2.36. The stock is down by about 43% year-to-date, according to data from&nbsp;<a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/12/42429588/gms-cruise-exit-draws-sharp-reaction-from-co-founder-kyle-vogt-tesla-ceo-elon-musk-says-autonomous-driving-is-a-very-hard-problem" target="_blank" rel="noreferrer noopener">GM&#8217;s Cruise Exit Draws Sharp Reaction From Co-Founder Kyle Vogt: Tesla CEO Elon Musk Says Autonomous Driving Is A ‘Very Hard Problem&#8217;</a></li>
</ul>
Photo courtesy: Lucid

Tech

LCID

Lucid's Gravity Gets Official Range Estimate: Higher Than Tesla's Model X, But Lower Than Its Own Air Sedan

Li Bang International announces pricing of initial public offering

U.S. IPO Weekly Recap: Sizable Tech And Biotech IPOs Are Joined By A Flurry Of Small Names

Ingram Micro and its private equity owner, Platinum Equity, sold 18.6 million shares at $22 each as the technology distributor returned to public trading in a busy week for the IPO market.

Ingram Micro Returns To Trading In Busy Week

Shares of Invizyne Technologies gained as much as 13% following the company's $15M initial public offering on Wednesday. LATEST IPOS AND DIRECT LIS...

Opening Day: Invizyne Technologies jumps after IPO

ACOG

ADUR

ALDFU

BEAGU

BYLT

CHARU

FBLA

FMFC

HSPTU

HUHU

INGM

IZTC

LBGJ

NAMI

OACCU

ROLR

SEPN

SNYR

TDACU

Press Releases

Li Bang International Corporation Inc. Announces Pricing of Initial Public Offering

Li Bang International Corporation Inc. Announces Closing of Initial Public Offering

Li Bang International Corporation Inc. Reports Financial Results for Fiscal Year 2024

Li Bang International Corporation Inc. Announces Underwriters' Full Exercise of Over-Allotment Option

Comments

Li Bang International

Li Bang International (LBGJ) Forecast

Li Bang International (NASDAQ:LBGJ) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga